Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.34 |
| ▸ | KDM1A | O60341 | 3/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
| ▸ | TACR1 | P25103 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25455143 | 1.00 | MGLL (0.35) | MGLLNAMPTOPRD1KDM1AMAOB | |
| SCHEMBL21843313 | 1.00 | MGLL (0.35) | MGLLNAMPTOPRD1KDM1AMAOB | |
| SCHEMBL23653316 | 0.90 | MAOA (0.33) | NAMPTOPRD1KDM1AMAOBSSTR1 | |
| SCHEMBL21843460 | 0.90 | MAOA (0.33) | MGLLKDM1ASSTR1SSTR4MAOA | |
| SCHEMBL23178069 | 0.84 | MGLL (0.38) | MGLLKDM1AMAOA | |
| SCHEMBL21843468 | 0.81 | KDM1A (0.34) | KDM1AMAOBSSTR1SSTR4MAOA | |
| SCHEMBL21843369 | 0.81 | MGLL (0.47) | MGLLTACR1 | |
| SCHEMBL25455144 | 0.81 | MGLL (0.47) | MGLLTACR1 | |
| SCHEMBL21843360 | 0.81 | POLB (0.43) | MGLLKDM1AMAOBKCNH2 | |
| SCHEMBL21843333 | 0.80 | MGLL (0.35) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649245-B2 | Cyclopropylamine compound as LSD1 inhibitor and use thereof | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649245-B2 | Cyclopropylamine compound as LSD1 inhibitor and use thereof | KDM1B, KDM1A, KDM7A | MGLL 2660/4885NAMPT 1266/4885OPRD1 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.